HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Capewell, S Articles by O’Flaherty, M Search for Related Content PubMed PubMed Citation Articles by Capewell, S Articles by O’Flaherty, M Topic Collections Relevant Article

Maximising secondary prevention therapies in patients with coronary heart disease

Division of Public Health, University of Liverpool, UK

Correspondence to:
Dr S Capewell, Division of Public Health, Whelan Building, Quadrangle, University of Liverpool, L69 3GB, UK; m.oflaherty@liverpool.ac.uk

The first 150 words of the full text of this article appear below.

Population-based primary prevention strategies are the only affordable solution for most developing countries. However, wealthier countries have the luxury of being able to support the complementary strategies of primary and secondary prevention. Ideally, almost all patients with coronary heart disease (CHD) can change their behaviour (smoking cessation, healthy diets and exercise-based rehabilitation) and receive secondary prevention medications (antiplatelet therapy, statins, ACE inhibitors and β-blockers, if there are no specific clinical contraindications).¹

Secondary prevention drugs are important; they may explain about 10% of the fall in CHD death rates seen in the UK population between 1981 and 2000, much as in the USA between 1980 and 2000 and elsewhere.^{2 3} Furthermore, secondary prevention medicine is relatively cheap and cost effective.⁴

Recognising that uptake by 100% of eligible patients with CHD might be unrealistic, the UK CHD National Service Framework (NSF) in 1999 sensibly started with 80% targets. Yet even these remain challenging, . . . [Full text of this article]

Relevant Article

Trends in secondary prevention of ischaemic heart disease in the UK 1994–2005: use of individual and combination treatment

S DeWilde, I M Carey, N Richards, P H Whincup, and D G Cook
Heart 2008 94: 83-88. [Abstract] [Full Text] [PDF]